The Archive · 5 posts
Unlocking life-saving solutions! 🚀 Fusion Antibodies PLC (FAB) leads in drug discovery with cutting-edge biotech innovation. 🔬
Fusion Antibodies reports 9% revenue growth, margins up to 50%, cash doubles to £1m+, and strategic wins with larger pharma clients. Cautiously optimistic FY2027 outlook.
May 5, 2026
Showing 4 of 5 posts
Fusion Antibodies sells IP for a £250k year-end revenue boost, supporting client Finn Therapeutics' fundraising in tough biotech markets.
JoshuaMarch 30, 2026
Fusion Antibodies reduces losses by 32% as its OptiMAL antibody platform nears commercial launch in December 2025, signalling a positive financial shift.
JoshuaNovember 24, 2025
Fusion Antibodies sees 73% revenue growth and secures key U.S. patent for OptiMAL, signalling a strategic shift towards IP-led growth and improved financials.
JoshuaSeptember 4, 2025
Fusion Antibodies' FY2025: 71% revenue surge to £1.96m. Strategic partnerships, FMI grant, and £1.17m R&D fundraise drive growth.
JoshuaMay 6, 2025
September 4, 2025